Trial Profile
A Matched Intervention Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Liver injury
- Focus Therapeutic Use
- 05 Apr 2021 Status changed from recruiting to withdrawn prior to enrolment as unable to recruit due to COVID 19.
- 30 Mar 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2023.
- 30 Mar 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2023.